InvestorsHub Logo
Followers 89
Posts 6835
Boards Moderated 1
Alias Born 09/18/2009

Re: OneDay4488 post# 39537

Friday, 06/16/2023 10:36:26 PM

Friday, June 16, 2023 10:36:26 PM

Post# of 43316
Novavax just issued a PR saying:

"PR NEWSWIRE
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall"

https://newsfilter.io/latest/fda-approvals

They're up 1.3% today on the excellent news.

We're up 6 - 20% with no PR.

I think both valuations simply reflect that regulators feel empowered to abuse their discretionary authority with impunity.

But this is a big world. It is not prepared with a proactive virulent response plan, as lenz is singularly essential to develop, preferably in an exclusive collaboration with Novavax.

Novavax recently announced:

"U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Feb 13, 2023"

https://ir.novavax.com/2023-02-13-U-S-Government-and-Novavax-Extend-Partnership,-Securing-Up-to-1-5-Million-Additional-Doses-of-Novavax-COVID-19-Vaccine

What SHOULD happen is that the lenz/vaccine/anti-viral cocktail should be the standard of care (SOC) for covid prevention. At the least, until that truth becomes self-evident, the lenz cocktail should be extended to family members of infected patients as a post-exposure prophylaxis. It should likewise be extended to seniors and those who are immuno-compromised as a pre-exposure prophylaxis.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.